Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) has scheduled the release of its fourth quarter and full year 2024 financial results for Wednesday, February 19, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. U.S. EST on the same day to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Conference Call Details
Date: Wednesday, February 19, 2025
Time: 5:00 p.m. U.S. EST
Webcast:

A replay of the conference call will be available on the investor relations website.
To participate in the live Q&A session, please register using this link to receive an email confirming your registration.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through its relentless drive to deliver better health care outcomes. We develop, manufacture, and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees, and investors. For more information, visit and connect with us on LinkedIn.

"Bausch Health Logo"

Bausch Health's fourth quarter and full year 2024 results will provide investors with valuable insights into the company's financial performance and strategic initiatives. Key metrics to focus on include revenue growth, adjusted EBITDA, net income or loss, and guidance for revenue, adjusted EBITDA, and adjusted operating cash flow. Additionally, investors should analyze the performance of each segment, including Salix, International, Solta Medical, Diversified, and Bausch + Lomb, to identify the key drivers of the company's growth and assess the potential for future expansion.


Table showing Bausch Health's revenue growth and adjusted EBITDA trends over the past year.


Bausch Health has demonstrated consistent revenue growth and improved adjusted EBITDA over the past year, as evidenced by the following trends:

* In the second quarter of 2024, Bausch Health reported total consolidated revenues of $2.40 billion, up 11% on a reported basis and 8% on an organic basis compared to the same period in 2023.
* In the third quarter of 2024, the company reported total consolidated revenues of $2.51 billion, up 12% on a reported basis and 9% on an organic basis compared to the same period in 2023.
* In the second quarter of 2024, Bausch Health's consolidated adjusted EBITDA attributable to Bausch Health Companies Inc. was $798 million, up 10% compared to the same period in 2023.
* In the third quarter of 2024, the company's consolidated adjusted EBITDA attributable to Bausch Health Companies Inc. was $909 million, up 10% compared to the same period in 2023.

These trends indicate a strong financial performance, with the company's diverse product portfolio and geographic footprint driving growth across various segments. Improved operational efficiency and cost management have also led to increased adjusted EBITDA, reflecting the company's commitment to enhancing profitability.

"Bausch Health Products"

Investors should also consider the primary drivers of Bausch Health's revenue growth, which have contributed significantly to the company's overall performance. These drivers include:

* Growth in all segments, with the Bausch + Lomb segment being the most significant contributor to the overall revenue increase.
* Strong performance in the Salix segment, driven by products such as Xifaxan®, Relistor®, and Trulance®.
* International segment growth, led by double-digit growth in Canada and solid organic growth in Latin America.
* Solta Medical segment growth, driven by strong demand in South Korea and China.
* Diversified segment growth, primarily attributable to increases in sales in Dermatology and Neurology.

By focusing on these key financial metrics and trends, investors can gain a comprehensive understanding of Bausch Health's performance and make informed decisions about the company's prospects. The upcoming earnings call and financial results will provide valuable insights into the company's strategic initiatives and financial health, enabling investors to assess the potential for future growth and expansion.